Related Experiment Video
Updated: Jul 14, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Reversible cardiomyopathies
Rangadham Nagarakanti1, David Whellan, Sharon Rubin
1Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Insights
Cardiomyopathy, a leading cause of heart failure, includes potentially reversible nonischemic types. Early diagnosis of heart failure etiology is crucial for better prognosis and treatment.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Cardiomyopathy encompasses diverse myocardial disorders leading to cardiac dysfunction.
- Heart failure prevalence is high and increasing, with cardiomyopathy being a leading cause of hospitalization in older adults.
- Cardiomyopathy contributes significantly to healthcare costs and lost productivity.
Purpose of the Study:
- To highlight the prevalence and significance of nonischemic cardiomyopathy.
- To emphasize the importance of early and precise diagnosis for prognosis and treatment.
- To underscore the better prognosis associated with reversible nonischemic cardiomyopathies.
Main Methods:
- Review of epidemiological data and clinical trial findings.
- Analysis of the prevalence of ischemic versus nonischemic cardiomyopathy.
- Examination of prognostic differences based on cardiomyopathy etiology.
Main Results:
- Cardiomyopathy affects millions, causing significant healthcare burden.
- Ischemic cardiomyopathy constitutes approximately half of cases.
- Potentially reversible nonischemic cardiomyopathy ranges from 20% to 50% in clinical trials.
Conclusions:
- Early and accurate diagnosis of heart failure etiology is critical.
- Reversible nonischemic cardiomyopathies may have a better prognosis.
- Understanding cardiomyopathy subtypes informs effective patient management and treatment strategies.
Abstract:
Cardiomyopathy represents a diverse and heterogenous group of disorders affecting the myocardium and ultimately resulting in cardiac dysfunction. The prevalence of heart failure is high (5 million symptomatic patients in the United States) and increasing. Cardiomyopathy is the leading cause of hospitalization in patients older than 65 years of age, resulting in enormous healthcare expenditure and lost productivity. Ischemic cardiomyopathy accounts for about half of these patients, but in several large clinical trials the prevalence of potentially reversible nonischemic cardiomyopathy is also significant, ranging from 20% to 50%. There is epidemiological evidence that the prognosis of these reversible nonischemic cardiomyopathies is better than ischemic or other nonreversible cardiomyopathies. Early and precise diagnosis of the etiology of heart failure is important for determining prognosis and effective treatments.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction

